Vaxcyte Says Topline Results From OPUS-1 Pivotal Adult Phase 3 Trial Of VAX-31, a 31-valent Pneumococcal Conjugate Vaccine Candidate, Met All Prespecified Primary Endpoints Across Age Groups Studied Compared To Prevnar 20 And/Or Capvaxive
VAX-31 Met All Prespecified Primary Endpoints Across Age Groups Studied Compared to Prevnar 20 (PCV20) and/or Capvaxive (PCV21)Prespecified Co-Primary Immunogenicity Endpoints: In Adults 50 and Older, All 28 VAX-31
Vaxcyte's new vaccine passed all its main tests in adults. This means the medicine worked as well or better than competitors in the study.
Last session drawn · prints held ~15 minutes · licensed exchange data
Source: Benzinga · Read the original report at the publisher. Headline and figures shown for context; data may be delayed.
Disclosure: Educational and informational purposes only. Not financial advice. We educate, not advise. Market data may be delayed up to 15 minutes unless marked real-time. Past performance is not indicative of future results.